Cargando…

Prognostic values of long noncoding RNA in bone metastasis of prostate cancer: A systematic review and meta-analysis

INTRODUCTION: Recent studies have shown that long non-coding RNAs are closely related to the occurrence and development of prostate cancer bone metastasis, and can be used as biomarkers to predict the prognosis of patients. Therefore, this study aimed to systematically evaluate the relationship betw...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Silu, Zhu, Yanli, Zhang, Xue, Chen, Siyu, Liu, Shuang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986415/
https://www.ncbi.nlm.nih.gov/pubmed/36890836
http://dx.doi.org/10.3389/fonc.2023.1085464
_version_ 1784901159698300928
author Song, Silu
Zhu, Yanli
Zhang, Xue
Chen, Siyu
Liu, Shuang
author_facet Song, Silu
Zhu, Yanli
Zhang, Xue
Chen, Siyu
Liu, Shuang
author_sort Song, Silu
collection PubMed
description INTRODUCTION: Recent studies have shown that long non-coding RNAs are closely related to the occurrence and development of prostate cancer bone metastasis, and can be used as biomarkers to predict the prognosis of patients. Therefore, this study aimed to systematically evaluate the relationship between the expression levels of long non-coding RNAs and the prognosis of patients. METHODS: The studies of lncRNA in prostate cancer bone metastasis from Pubmed, Cochrane library, Embase, Ebsco, Web of science, Scopus, Ovid databases were analyzed, and Stata 15 was used for meta-analysis. Associations between lncRNA expression and patients’ overall survival (OS) and bone metastasis-free survival (BMFS) were assessed by correlation analysis with pooled hazard ratios (HR) and 95% confidence intervals (CI). Furthermore, the results were validated using GEPIA2 and UALCAN, online database based on TCGA. Subsequently, the molecular mechanisms of the included lncRNAs were predicted based on the LncACTdb 3.0 database and the lnCAR database. Finally, we used clinical samples to validate lncRNAs that were significantly different in both databases. RESULTS: A total of 5 published studies involving 474 patients were included in this meta-analysis. The results showed that lncRNA overexpression was significantly associated with lower OS (HR = 2.55, 95% CI: 1.69 - 3.99, p < 0.05) and lower BMFS (OR = 3.16, 95% CI: 1.90 - 5.27, p < 0.05) in patients with prostate cancer bone metastasis. Based on validation from the GEPIA2 and UALCAN online databases, SNHG3 and NEAT1 were significantly up-regulated in prostate cancer. Further functional prediction showed that the lncRNAs included in the study were involved in regulating the occurrence and development of prostate cancer through the ceRNA axis. The result of clinical samples showed that SNHG3 and NEAT1 were expressed in prostate cancer bone metastasis at higher levels than in primary tumors. CONCLUSIONS: LncRNA can be used as a novel predictive biomarker for predicting poor prognosis in patients with prostate cancer bone metastasis, which is worthy of clinical validation.
format Online
Article
Text
id pubmed-9986415
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99864152023-03-07 Prognostic values of long noncoding RNA in bone metastasis of prostate cancer: A systematic review and meta-analysis Song, Silu Zhu, Yanli Zhang, Xue Chen, Siyu Liu, Shuang Front Oncol Oncology INTRODUCTION: Recent studies have shown that long non-coding RNAs are closely related to the occurrence and development of prostate cancer bone metastasis, and can be used as biomarkers to predict the prognosis of patients. Therefore, this study aimed to systematically evaluate the relationship between the expression levels of long non-coding RNAs and the prognosis of patients. METHODS: The studies of lncRNA in prostate cancer bone metastasis from Pubmed, Cochrane library, Embase, Ebsco, Web of science, Scopus, Ovid databases were analyzed, and Stata 15 was used for meta-analysis. Associations between lncRNA expression and patients’ overall survival (OS) and bone metastasis-free survival (BMFS) were assessed by correlation analysis with pooled hazard ratios (HR) and 95% confidence intervals (CI). Furthermore, the results were validated using GEPIA2 and UALCAN, online database based on TCGA. Subsequently, the molecular mechanisms of the included lncRNAs were predicted based on the LncACTdb 3.0 database and the lnCAR database. Finally, we used clinical samples to validate lncRNAs that were significantly different in both databases. RESULTS: A total of 5 published studies involving 474 patients were included in this meta-analysis. The results showed that lncRNA overexpression was significantly associated with lower OS (HR = 2.55, 95% CI: 1.69 - 3.99, p < 0.05) and lower BMFS (OR = 3.16, 95% CI: 1.90 - 5.27, p < 0.05) in patients with prostate cancer bone metastasis. Based on validation from the GEPIA2 and UALCAN online databases, SNHG3 and NEAT1 were significantly up-regulated in prostate cancer. Further functional prediction showed that the lncRNAs included in the study were involved in regulating the occurrence and development of prostate cancer through the ceRNA axis. The result of clinical samples showed that SNHG3 and NEAT1 were expressed in prostate cancer bone metastasis at higher levels than in primary tumors. CONCLUSIONS: LncRNA can be used as a novel predictive biomarker for predicting poor prognosis in patients with prostate cancer bone metastasis, which is worthy of clinical validation. Frontiers Media S.A. 2023-02-20 /pmc/articles/PMC9986415/ /pubmed/36890836 http://dx.doi.org/10.3389/fonc.2023.1085464 Text en Copyright © 2023 Song, Zhu, Zhang, Chen and Liu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Song, Silu
Zhu, Yanli
Zhang, Xue
Chen, Siyu
Liu, Shuang
Prognostic values of long noncoding RNA in bone metastasis of prostate cancer: A systematic review and meta-analysis
title Prognostic values of long noncoding RNA in bone metastasis of prostate cancer: A systematic review and meta-analysis
title_full Prognostic values of long noncoding RNA in bone metastasis of prostate cancer: A systematic review and meta-analysis
title_fullStr Prognostic values of long noncoding RNA in bone metastasis of prostate cancer: A systematic review and meta-analysis
title_full_unstemmed Prognostic values of long noncoding RNA in bone metastasis of prostate cancer: A systematic review and meta-analysis
title_short Prognostic values of long noncoding RNA in bone metastasis of prostate cancer: A systematic review and meta-analysis
title_sort prognostic values of long noncoding rna in bone metastasis of prostate cancer: a systematic review and meta-analysis
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986415/
https://www.ncbi.nlm.nih.gov/pubmed/36890836
http://dx.doi.org/10.3389/fonc.2023.1085464
work_keys_str_mv AT songsilu prognosticvaluesoflongnoncodingrnainbonemetastasisofprostatecancerasystematicreviewandmetaanalysis
AT zhuyanli prognosticvaluesoflongnoncodingrnainbonemetastasisofprostatecancerasystematicreviewandmetaanalysis
AT zhangxue prognosticvaluesoflongnoncodingrnainbonemetastasisofprostatecancerasystematicreviewandmetaanalysis
AT chensiyu prognosticvaluesoflongnoncodingrnainbonemetastasisofprostatecancerasystematicreviewandmetaanalysis
AT liushuang prognosticvaluesoflongnoncodingrnainbonemetastasisofprostatecancerasystematicreviewandmetaanalysis